

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/160331 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) A61K 39/395 (2006.01)
C12N 15/63 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01) C12N 15/64 (2006.01)

(21) International Application Number:

PCT/US2025/012854

(22) International Filing Date:

24 January 2025 (24.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202410115198.1 26 January 2024 (26.01.2024) CN

(71) Applicant: **FUTUREGEN BIOPHARMACEUTICAL (BEIJING) CO., LTD.** [CN/CN]; 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN).

(72) Inventor; and

(71) Applicant (for LC only): **LI, Yun** [US/CN]; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN).

(72) Inventors: **JIN, Zhaoyu**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **YANG, Yaping**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **LI, Yue**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **LI, Feng**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **ZHANG, Lina**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **ZHAO, An**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye-

jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **HUO, Naifan**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN). **CAO, An**; C/o Futuregen Biopharmaceutical (beijing) Co., Ltd, 2-201, Building 1, #16 Baoshennan jie, Daxing Shengwuyiyao Chanye jidi, Zhongguancun Science Park, Daxing District, Beijing, 102629 (CN).

(74) Agent: **LU, Yu** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TL1A AND USE THEREOF

(57) Abstract: The present disclosure relates to antibodies that specifically binding to TL1A and uses thereof, in particular to antibodies that specifically bind to TL1A or antigen-binding fragments thereof, nucleic acids encoding the antibodies or antigen-binding fragments thereof, vectors containing the nucleic acids, and host cells containing the nucleic acids or the vectors. Pharmaceutical compositions comprising the antibodies as well as methods of treatment using the antibodies are also provided.

WO 2025/160331 A1